368 related articles for article (PubMed ID: 34479888)
1. Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.
Satoh K; Morisawa S; Okuyama M; Nakae H
BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34479888
[TBL] [Abstract][Full Text] [Related]
2. Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Suh KJ; Lee JY; Shin DY; Koh Y; Bang SM; Yoon SS; Park S; Kim I; Lee JO
Int J Hematol; 2017 Aug; 106(2):229-239. PubMed ID: 28378056
[TBL] [Abstract][Full Text] [Related]
3. Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors.
Aslan NA; Hıncal HO; Elver Ö; Erol V; Güler N
J Oncol Pharm Pract; 2023 Mar; 29(2):511-516. PubMed ID: 35821583
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of nilotinib-induced pleural effusion with prednisone.
Chakraborty K; Bossaer JB; Patel R; Krishnan K
J Oncol Pharm Pract; 2013 Jun; 19(2):175-7. PubMed ID: 23154573
[TBL] [Abstract][Full Text] [Related]
5. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
[TBL] [Abstract][Full Text] [Related]
6. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib.
Masiello D; Gorospe G; Yang AS
J Hematol Oncol; 2009 Nov; 2():46. PubMed ID: 19909541
[TBL] [Abstract][Full Text] [Related]
7. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
[TBL] [Abstract][Full Text] [Related]
8. Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Maral S; Bakanay SM; Kucuksahin O; Dilek I
J Oncol Pharm Pract; 2020 Apr; 26(3):738-741. PubMed ID: 31359838
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia.
Aoyama R; Ishikawa J; Harada K
J Cardiol; 2020 Feb; 75(2):203-207. PubMed ID: 31416783
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib-induced chylothorax: report of a case and review of the literature.
Chen B; Wu Z; Wang Q; Li W; Cheng D
Invest New Drugs; 2020 Oct; 38(5):1627-1632. PubMed ID: 32248338
[TBL] [Abstract][Full Text] [Related]
12. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
13. An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia after Experiencing Pleural Effusion during Dasatinib Therapy.
McBride A; Brokars J; Reddy SR; Chang E; Tarbox MH; LeBlanc TW
Acta Haematol; 2023; 146(4):259-266. PubMed ID: 37037194
[TBL] [Abstract][Full Text] [Related]
14. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy.
Kim D; Goh HG; Kim SH; Cho BS; Kim DW
Int J Hematol; 2011 Oct; 94(4):361-371. PubMed ID: 21901399
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Miura M
Biol Pharm Bull; 2015; 38(5):645-54. PubMed ID: 25947908
[TBL] [Abstract][Full Text] [Related]
17. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous manifestation of pleural effusion and acute renal failure associated with dasatinib: a case report.
Kaiafa G; Kakaletsis N; Savopoulos C; Perifanis V; Giannouli A; Papadopoulos N; Zisekas S; Hatzitolios AI
J Clin Pharm Ther; 2014 Feb; 39(1):102-5. PubMed ID: 24188312
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Rousselot P; Mollica L; Guilhot J; Guerci A; Nicolini FE; Etienne G; Legros L; Charbonnier A; Coiteux V; Dartigeas C; Escoffre-Barbe M; Roy L; Cony-Makhoul P; Dubruille V; Gardembas M; Huguet F; Réa D; Cayssials E; Guilhot F; Bergeron A; Molimard M; Mahon FX; Cayuela JM; Busque L; Bouchet S
Br J Haematol; 2021 Jul; 194(2):393-402. PubMed ID: 34195988
[TBL] [Abstract][Full Text] [Related]
20. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
